Social Anxiety and MDMA-assisted Therapy Investigation: a Novel Clinical Trial Protocol

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2023 Jul 31

PMID 37520237

Authors

M Kati Lear

Sarah M Smith

Brian Pilecki

Chris S Stauffer

Jason B Luoma

Affiliations

Soon will be listed here.

Abstract

Background: Social anxiety disorder (SAD) is a serious and prevalent psychiatric condition that heavily impacts social functioning and quality of life. Though efficacious treatments exist for SAD, remission rates remain elevated and a significant portion of those affected do not access effective treatment, suggesting the need for additional evidence-based treatment options. This paper presents a protocol for an open-label pilot study of MDMA-assisted therapy (MDMA-AT) for social anxiety disorder. The study aims to assess preliminary treatment outcomes, feasibility and safety, and psychological and physiological processes of change in the treatment of SAD with MDMA-AT. A secondary aim includes the development of a treatment manual for MDMA-AT for SAD.

Method: The outlined protocol is a randomized, open-label delayed treatment study. We will recruit 20 participants who meet criteria with moderate-to-severe social anxiety disorder (SAD) of the generalized subtype. Participants will be randomly assigned to an immediate treatment ( = 10) or delayed treatment condition ( = 10). Those in the immediate treatment condition will proceed immediately to active MDMA-AT consisting of three preparation sessions, two medicine sessions in which they receive oral doses of MDMA, and six integration sessions over approximately a 16-week period. The delayed treatment condition will receive the same intervention after a 16-week delay. Our primary outcome is SAD symptom reduction as measured by the Liebowitz Social Anxiety Scale administered by blinded raters at post-treatment and 6 month follow up. Secondary outcomes include changes in functional impairment, feasibility and safety measures, and novel therapeutic processes of change including shame and shame-related coping, belongingness, self-concealment, and self-compassion at post-treatment. Exploratory outcomes are also discussed.

Discussion: The results of this pilot trial advance the field's understanding of the acceptability and potential effectiveness of MDMA-AT for social anxiety disorder and provide an overview of relevant therapeutic mechanisms unique to SAD. We hope findings from this protocol will inform the design of subsequent larger-scale randomized controlled trials (RCT) examining the efficacy of MDMA-AT for SAD.

Clinical Trial Registration: https://clinicaltrials.gov/, NCT05138068.

Citing Articles

Bringing MDMA-assisted therapy for PTSD to traditional healthcare systems: tending to set and setting.

Perivoliotis D, Knopp K, Remick S, Kaigle A, Stauffer C, Khalifian C Front Psychiatry. 2025; 16:1433999.

PMID: 39925875 PMC: 11804254. DOI: 10.3389/fpsyt.2025.1433999.

Dysfunction of the Neurovascular Unit by Psychostimulant Drugs.

Thuy Lu Vo T, Shin D, Ha E, Seo J Int J Mol Sci. 2023; 24(20).

PMID: 37894832 PMC: 10606839. DOI: 10.3390/ijms242015154.

References

Barkowski S, Schwartze D, Strauss B, Burlingame G, Barth J, Rosendahl J . Efficacy of group psychotherapy for social anxiety disorder: A meta-analysis of randomized-controlled trials. J Anxiety Disord. 2016; 39:44-64. DOI: 10.1016/j.janxdis.2016.02.005. View

Haberman A, Shahar B, Bar-Kalifa E, Zilcha-Mano S, Diamond G . Exploring the process of change in emotion-focused therapy for social anxiety. Psychother Res. 2018; 29(7):908-918. DOI: 10.1080/10503307.2018.1426896. View

Taylor C, Bomyea J, Amir N . Malleability of attentional bias for positive emotional information and anxiety vulnerability. Emotion. 2011; 11(1):127-138. PMC: 3208375. DOI: 10.1037/a0021301. View

Bruffaerts R, Harris M, Kazdin A, Vigo D, Sampson N, Chiu W . Perceived helpfulness of treatment for social anxiety disorder: findings from the WHO World Mental Health Surveys. Soc Psychiatry Psychiatr Epidemiol. 2022; 57(10):2079-2095. PMC: 9458773. DOI: 10.1007/s00127-022-02249-3. View

Huhn M, Tardy M, Spineli L, Kissling W, Forstl H, Pitschel-Walz G . Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry. 2014; 71(6):706-15. DOI: 10.1001/jamapsychiatry.2014.112. View

Mithoefer M, Feduccia A, Jerome L, Mithoefer A, Wagner M, Walsh Z . MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019; 236(9):2735-2745. PMC: 6695343. DOI: 10.1007/s00213-019-05249-5. View

Passie T, Hartmann U, Schneider U, Emrich H, Kruger T . Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion. Med Hypotheses. 2005; 64(5):899-903. DOI: 10.1016/j.mehy.2004.11.044. View

Goessl V, Curtiss J, Hofmann S . The effect of heart rate variability biofeedback training on stress and anxiety: a meta-analysis. Psychol Med. 2017; 47(15):2578-2586. DOI: 10.1017/S0033291717001003. View

Baggott M, Coyle J, Siegrist J, Garrison K, Galloway G, Mendelson J . Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol. 2016; 30(4):378-87. DOI: 10.1177/0269881115626348. View

10.

Markey P, Funder D, Ozer D . Complementarity of interpersonal behaviors in dyadic interactions. Pers Soc Psychol Bull. 2004; 29(9):1082-90. DOI: 10.1177/0146167203253474. View

11.

Luoma J, Chwyl C, Bathje G, Davis A, Lancelotta R . A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. J Psychoactive Drugs. 2020; 52(4):289-299. PMC: 7736164. DOI: 10.1080/02791072.2020.1769878. View

12.

de la Vega D, Giner L, Courtet P . Suicidality in Subjects With Anxiety or Obsessive-Compulsive and Related Disorders: Recent Advances. Curr Psychiatry Rep. 2018; 20(4):26. DOI: 10.1007/s11920-018-0885-z. View

13.

Carter C, Grippo A, Pournajafi-Nazarloo H, Ruscio M, Porges S . Oxytocin, vasopressin and sociality. Prog Brain Res. 2008; 170:331-6. DOI: 10.1016/S0079-6123(08)00427-5. View

14.

Heimberg R, Horner K, Juster H, Safren S, Brown E, Schneier F . Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med. 1999; 29(1):199-212. DOI: 10.1017/s0033291798007879. View

15.

Romano M, Moscovitch D, Huppert J, Reimer S, Moscovitch M . The effects of imagery rescripting on memory outcomes in social anxiety disorder. J Anxiety Disord. 2019; 69:102169. DOI: 10.1016/j.janxdis.2019.102169. View

16.

Loerinc A, Meuret A, Twohig M, Rosenfield D, Bluett E, Craske M . Response rates for CBT for anxiety disorders: Need for standardized criteria. Clin Psychol Rev. 2015; 42:72-82. DOI: 10.1016/j.cpr.2015.08.004. View

17.

Rasmusson A, Charney D . Animal models of relevance to PTSD. Ann N Y Acad Sci. 1997; 821:332-51. DOI: 10.1111/j.1749-6632.1997.tb48290.x. View

18.

MacIntyre M, Zare M, Williams M . Anxiety-Related Disorders in the Context of Racism. Curr Psychiatry Rep. 2023; 25(2):31-43. PMC: 9841144. DOI: 10.1007/s11920-022-01408-2. View

19.

Luoma J, Shahar B, Lear M, Pilecki B, Wagner A . Potential processes of change in MDMA-Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self-transcendence, and therapeutic relationships. Hum Psychopharmacol. 2021; 37(3):e2824. PMC: 9285360. DOI: 10.1002/hup.2824. View

20.

Heifets B, Malenka R . MDMA as a Probe and Treatment for Social Behaviors. Cell. 2016; 166(2):269-272. DOI: 10.1016/j.cell.2016.06.045. View